Aditya Sarawgi

Tue, Jun 24, 2025, 1:46 AM2 min read

Canonsburg, Pennsylvania-based Viatris Inc. (VTRS) is a global pharmaceutical and healthcare corporation. With a market cap of $10.4 billion, Viatris operates through Developed Markets, Greater China, JANZ (Japan, Australia, and New Zealand), and Emerging Markets segments.

Companies worth $10 billion or more are generally described as "large-cap stocks." Viatris fits right into that category, with its market cap exceeding this threshold, reflecting its substantial size and influence in the specialty & generic drug manufacturing industry. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs).

• The Next Trillion-Dollar Boom? 3 Stocks to Buy with 300 Million Humanoid Robots on the Horizon.

• Warren Buffett’s Berkshire Hathaway Now Pays 5% of All Corporate Income Taxes in America

• Meta’s Mark Zuckerberg Says the Technology They’re Developing Will ‘See What You See and Hear What You Hear’

• Our exclusive Barchart Brief newsletter is your FREE midday guide to what's moving stocks, sectors, and investor sentiment - delivered right when you need the info most. Subscribe today!

Viatris stock touched its 52-week high of $13.55 on Nov. 25, 2024, and is currently trading 34.7% below that peak. Over the past three months, VTRS stock has dropped 3.3%, significantly underperforming the S&P 500 Index’s ($SPX) 6.3% gains during the same time frame.

Viatris performance has remained lackluster over the longer term as well. VTRS stock has plummeted 28.9% on a YTD basis and 15.5% over the past 52 weeks, notably underperforming SPX’s 2.4% uptick in 2025 and 10.3% surge over the past year.

VTRS stock has traded consistently below its 200-day moving average since mid-January and below its 50-day moving average between mid-December 2024 and early May, underscoring its bearish price movement.

Viatris’ stock prices gained 5.7% after the release of its better-than-expected Q1 results on May 8. Its adjusted operational revenues for the quarter dropped 2% compared to the year-ago quarter. However, its topline of $3.3 billion surpassed the consensus estimates by 81 bps. Meanwhile, the company’s adjusted EPS declined 25.4% year-over-year to $0.50, but surpassed the consensus estimates by 2%, boosting investor confidence.

Meanwhile, Viatris has significantly underperformed its peer Sanofi's (SNY) marginal 10 bps dip in 2025 and a 2.1% uptick over the past 52 weeks.

Among the eight analysts covering the VTRS stock, the consensus rating is a “Hold.” Its mean price target of $10.91 suggests a 23.3% upside potential from current price levels.

On the date of publication, Aditya Sarawgi did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. This article was originally published on Barchart.com